Category Patents/Designs/Trade Secrets

US Supreme Court Adopts International Exhaustion Of Patents (Part II): Addressing the New Competitive Landscape

Frederick M. Abbott writes: The US Supreme Court has created a new competitive landscape with its decision adopting international exhaustion of patents. For the pharmaceutical sector, we can expect an initial period of uncertainty as the US Food and Drug Administration (FDA) assesses the regulatory framework affected by the decision and as competing stakeholders advance their interests. In an earlier Inside Views contribution, I addressed the principal impact of the decision on the US pharmaceuticals market: downward pricing pressure.[1] This follow-on addresses some of the regulatory and access issues affected by the decision, observing that parallel trade in pharmaceutical products is a long-standing practice, that recently introduced US legislative proposals may shape the regulatory framework in the United States, and concluding with ways that access programs in favor of developing countries are protected.

US Ends Post-Sale Patent Rights

On 30 May, the US Supreme Court handed down yet another in a long series of rulings that cut back on the rights of patent owners. This time, the high court made it far more difficult for patentees to impose post-sale restrictions on the use or resale of their patented goods. The ruling should boost parallel imports into the US, increase competition throughout the American economy, lower prices for US consumers, and hurt the bottom line of many companies.

Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now

For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet.

IP And The Public Interest Premieres At WTO TRIPS Council Next Week

It has become a tradition at the World Trade Organization committee on intellectual property to have an agenda item on intellectual property and innovation, and next week's meeting is no exception. More noticeable on the agenda of the committee next week is an item on intellectual property and the public interest that addresses compulsory licensing.

New WHO Essential Medicines List: Antibiotics, Hepatitis C, Leukaemia, TB

The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year.

Industry, NGOs On Staff At WHO? Beware Of Revolving Doors, Some Say

The agreement found last year after months of intense discussion to avert the possibility of undue influence by outside actors at the World Health Organization is yet to be fully implemented. The World Health Assembly last week looked at progress and the process by which the WHO can temporarily welcome on its staff individuals from the private sector, civil society, philanthropic foundations, and academic institutions. Some countries questioned principles in this process but were told by the WHO that their comments would merely be recorded.

Polypills: Are Miracle Treatments Being Overlooked?

Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.